Abstract: Adult thymopoiesis is a multi-step process that in adult mice is highlighted by a 21-day cycle of coordinated journeying of progenitor cells between adult bone marrow and thymus. In the analogous human system, cell surface human leukocyte elastase (HLE CS ), the chemokine receptor CXCR4, and its ligand stromalderived factor-1 (SDF-1, CXCL12) are required for progenitor cells to vacate bone marrow. We have recently observed that the number of circulating CD4
INTRODUCTION
The three predominant blood cell subtypes are erythrocytes, granulocytes, and CD4 + lymphocytes. Growth factors such as erythropoietin and G-CSF are currently used therapeutically to mobilize erythroid and myeloid progenitor cells. Emerging information related to stem cell mobilization suggested to us that a fundamental and previously unrecognized function of the blood protein  1 PI is mobilization of CD4 + progenitor cells. Active  1 PI binds to a receptor complex central to cell migration that includes the chemokine stromal-derived factor-1 (SDF-1, CXCL12), its receptor CXCR4, and the  1 PI receptor, HLE CS (1) (2) (3) .
Blood cell migration occurs as the result of two discrete steps. First, the relevant receptors polarize at the leading edge of the cell, and second, these receptors are endocytosed at the trailing edge (4) . When integrins are involved in the receptor complex, cells attach to the tissue matrix. Subsequent endocytosis of the receptor complex at the trailing edge releases the cells from the tissue matrix (4) . Plasma membrane-associated proteinases at the attachment point do not act as proteinases, rather bind to their relevant proteinase inhibitors as receptor and ligand. When these proteinase receptors are in complex with their ligands, e.g.  1 PI-complexed HLE CS , conformational changes expose novel domains that attract nearby low-density lipoporotein (LDL) receptor complexes (4, 5) . Binding of the LDL receptor complex to the proteinase inhibitor complex induces their endocytosis which causes the cell to advance forward (4, 5) .
In earlier work, we established that antibodies reactive with HIV-1 gp120 also bind and inactivate human  1 PI, producing IgG- 1 PI immune complexes (6) . IgG- 1 PI immune complexes produce functional  1 PI deficiency in HIV-1 infected individuals. A single amino acid differentiates chimpanzee  1 PI from human  1 PI, and this difference is in the HIV-1 gp120 homologous domain, perhaps explaining the lack of progression of HIV-1 infected chimpanzees to AIDS (7) . Further, comparison of the amino acid sequences of human  1 PI, HIV-1, HIV-2, SIV, HTLV-1, and HTLV-2 reveals that all share homology with the hydrophobic core of the fusion domain of HIV-1 gp41 (LFLGFL), but only HIV-1 gp120 shares homology with  1 PI (6). We hypothesized that the insufficient  1 PI that attends HIV-1 disease might secondarily cause CD4 + lymphocytes to become trapped in tissue, unable to complete the second step of cell migration and be released into blood. We demonstrate herein that  1 PI augmentation induces substantial increases in CD4 + lymphocytes that cycle with a 23±3.5 day periodicity.
METHODS
Human Subjects. It was determined using the empirical correlation between  1 PI and CD4 + lymphocytes that a sample size of 2 HIV-1 + patients would be adequate two achieve a significance level with alpha = 0.05 and power of test = 0.8 between pre-and post-treatment CD4 + lymphocytes levels. Inclusion criteria for treatment were: i) active  1 PI below 11 M; ii) one year history with CD4 + lymphocytes at levels ranging between 150 and 300 cells/l; iii) absence of symptoms suggestive of HIV-1 disease progression; iv) adequate suppression of virus (<50 HIV RNA/ml); and v) history of compliance with antiretroviral medication. Due to the small size of the study and to avoid other complications of pregnancy, only male HIV-1 patients were enrolled. The half-life of Zemaira ® (purified  1 PI ) after infusion is 4.5 days, reaching steady state after 3-4 wks therapy (18) . CSL Behring contributed a sufficient quantity of Zemaira ® (lot# C405702) for administration of 8 weekly infusions at a dose of 120mg/kg.
Written informed consent was received from 4 HIV-1 patients designated Alpha, Beta, Gamma, and Delta. For comparison, blood was collected from 2 non-HIV-1 patients, both female, with a diagnosis of emphysema in the context of genetic  1 PI deficiency (PI ZZ -1 and PI ZZ -2, ages 52 and 53, respectively). In all cases, patients had never before received  1 PI augmentation therapy. After initiating therapy, an assessment of dosage and the quantity of donated Zemaira ® allowed for the extended treatment of patient Alpha for a total of 12 wks. Due to an insufficient number of serum samples from patient PI ZZ -2, only functional analyses of CD4 + lymphocytes are presented. Patient Gamma who was PPD positive and elderly had become PPD negative 2 yrs prior to the treatment presented here which is clinically interpreted as a loss of immune function. Patient Delta reported to the first infusion stating that due to unforeseen circumstances, his antiretroviral medication was interrupted for 4 days. Although there was no fever present or other indication of infection at the time of the first infusion, in follow-up analysis, this patient was found to have pre-treatment serum IL-2 levels of 51 pg/ml (normal is undetectable) and other atypical baseline measures indicative of an inflammatory response and exceeding study inclusion criteria including 454 CD4 + cells/l, 205 HIV RNA copies/ml, and 14 M  1 PI. Thus, blood from patient Delta was analyzed for the purpose of assessing treatment response in the presence of systemic inflammation. Only pre-and post-treatment NFB activation, cytokine release, and lymphocyte phenotype were determined for this patient.
Blood was collected at each session and was sent to a contractor medical laboratory which provided independent measurement of the complete blood cell count (CBC) with differential, lipid panel, blood chemistry, lymphocyte panel, and HIV RNA. Periodically, kidney (BUN and creatinine) and liver function tests (ALT, AST) were monitored for potential immune complex disease, and all measurements were within the normal range. Lymphocyte function and phenotype analysis were performed by our laboratory. The study protocol was approved by CSL Behring and by the institutional review board of Cabrini Medical Center. No adverse effects were reported by any patient. Serum  1 PI levels. Active  1 PI was determined in once-thawed serum samples by our laboratory as previously described with the modification that endpoint, rather than kinetic, analysis was measured (19) . Briefly, the inhibition of porcine pancreatic elastase (PPE, Sigma, St. Louis, MO) that was specifically attributable to serum  1 PI was quantitated in the context of the serum concentration of  2 macroglobulin and its higher affinity for PPE relative to  1 PI. Lymphocyte phenotype analysis. Surface staining on whole blood was performed by incubating for 15 min at 23 o C with ASR type, fluorescently conjugated antibodies recognizing CD4, CD3, CD8, CD45RA, CD45RO, CXCR4, CCR5, CD34. CD25, and isotype controls (BD Biosciences). Cells were subsequently stained to detect HLE CS by incubating whole blood for an additional 15 min at 23 o C with rabbit anti-HLE (Biodesign, Kennebunkport, ME) or negative control rabbit IgG (Chemicon, Temecula, CA) which had been conjugated to Alexa Fluor 647 (Molecular Probes). At least 10,000 cells from each sample were acquired using a FACSCalibur flow cytometer. Markers on cells in the lymphocyte gate were quantitated, and CD4 + cells in the lymphocyte gate were validated using a contractor medical laboratory. Cell staining was analyzed using CellQuest (BD Biosciences) or FlowJo software (Tree Star, Inc., Ashland, OR). CD4 + lymphocyte functional analysis. CD4 + lymphocytes were negatively selected from PBMC using magnetic cell sorting as recommended by the manufacturer (Miltenyi Biotec, Auburn, CA). Isolated cells (1x10 6 cells/ml) were cultured in medium containing 10% FBS in 24-well tissue culture plates for 3 days at 37 o C, 5% CO 2 , in the presence or absence of stimulation antibodies reactive with CD2, CD3, and CD28 as recommended by the manufacturer (Miltenyi Biotec). Culture supernatants were measured by ELISA as recommended by the manufacturer (R&D Systems, Minneapolis, MN) for IL-2, IL-4, IL-10, and IFN.
Harvested CD4 + lymphocytes were examined for NFB phospho-epitope staining by flow cytometry as previously described (20) . Briefly, 1x10 6 cells/well in 96 well plates were fixed using 1.5% 
RESULTS

CD4
+ lymphocytes increase and CD8 + lymphocytes decrease in response to  1 PI replacement therapy.
To examine the interrelationship between  1 PI concentration and CD4 + lymphocyte numbers, data were examined from a blinded study conducted to monitor hematologic changes following weekly infusions of  1 PI (60 mg/kg) in 11 individuals with genetic  1 PI deficiency (PI ZZ ) who had never before received  1 PI therapy. Treatment with  1 PI caused an increase in lymphocytes in 10 of these individuals (data not shown), suggesting that such treatment might benefit HIV-1 + patients. Two HIV-1 patients, Alpha and Beta at different stages of disease (Table 1) received weekly infusions of 120 mg/kg  1 PI augmentation. Two additional HIV-1 patients, Gamma and Delta, with a priori evidence of abnormal immune status received the same therapy. The ability of Gamma to respond to antigen was impaired (positive PPD followed by negative PPD), and Delta exhibited systemic inflammation. Finally, 2 non-HIV-1 patients were included in the study, PI ZZ -1 and PI ZZ -2, who manifested normal numbers of CD4 + lymphocytes and a diagnosis of emphysema in the context of genetic  1 PI deficiency. The PI ZZ patients received half-dose weekly infusions of 60mg/kg  1 PI augmentation. Patients Delta and PI ZZ -2 were included only in CD4 + lymphocyte functional analyses (see Methods).
HIV-1 + patients Alpha, Beta, and Gamma ( Figure 1 
+ lymphocyte cycling is sinusoidal.
All patients exhibited cyclic changes in CD4 + lymphocytes ( Figure 3 ). Patients Alpha, Beta, and PI ZZ -1 exhibited sinusoidal changes in CD4 + lymphocytes with periodicity 23±3.5 days (Figure 3 ). Patient Gamma exhibited sinusoidal changes in CD4 + lymphocytes with periodicity of 15 days. Of important note, patient PI ZZ -1, but none of the HIV-1 patients, exhibited sinusoidal changes in CD8 + lymphocytes. In patient Alpha, the sinusoidal wave was damped exhibiting decreased amplitude. In patients Beta and Gamma, the oscillations sloped downward. The 5 week treatment period for patient PIzz-2 was insufficient for determining the occurrence of periodicity.
The CD4/CD8 ratio in patients Alpha, Beta, and PIzz-1 increased following 1PI therapy at a rate of 0.02±0.008 per week (Figure 1, 3 Glucocorticoids cause the release of granulocytes and lymphocytes from tissue, but the peak increase occurs within 6 hrs and dissipates within 24 hrs (8) . Glucocorticoid-induced demarginalized lymphocytes are unresponsive to stimulation. To determine whether  1 PI-mobilized CD4 + lymphocyte populations were functional, CD4 + lymphocytes were isolated from blood and cultured in stimulation media. (Figure 4b ). In parallel, patient Alpha and PIzz-1 as well as PI ZZ -2 expressed significantly lower CD4 + CD45RO + memory cells than the HIV-1 uninfected volunteers. However, these differences did not appear to be related to  1 PI therapy since the percentage of naïve and memory cells remained steady in each patient throughout therapy. All other surface markers measured were normal (not depicted). These results suggest that the phenotypic profile of CD4 + lymphocytes unique to each individual was maintained within the new generation of lymphocytes.
DISCUSSION
The processes that renew the adult human CD4 + lymphocyte population are poorly understood and the sinusoidal changes we observed may offer insight into the renewal mechanisms. While cyclic variation in circulating CD4
+ lymphocytes has not been previously described, cyclic neutropenia occurs with an average 21-28 day periodicity and is caused by mutations in the  1 PI receptor, HLE CS (9) . The  1 PI-induced in situ proliferation of CD4 + lymphocytes (24-48 h) (10) or the release of functional CD4 + lymphocytes from lymph tissue into circulation as occurs in an acute phase reaction (4-24 h) (11) may explain cycling, but neither of these explanations account for the 2 wk lag in appearance and 23 day periodicity. Rather, a multi-step process is implied.
In adult mice, thymopoiesis is a multi-step process defined by a 21-day cycle. The process involves the cyclic accumulation of progenitor cells in the adult bone marrow (3-5 wk), export of progenitor cells from the bone marrow thereby vacating the bone marrow niche (~1 wk), temporally coordinated (13) , and as a consequence the number of CD8 + lymphocytes increases thereby producing a decreased CD4/CD8 ratio (13, 14) .
In the analogous human system, HLE CS , CXCR4, and CXCL12 are required for progenitor cells to vacate bone marrow, (2, 15) . In the present study, a lower pre-treatment CD8 percentage was inversely correlated with  1 PI-induced expansion of CD4 + lymphocytes as would be expected if treatment had re-established positive selection. Thus, we propose that the observed  1 PI-induced changes in CD4 + and CD8 + lymphocyte numbers resulted from the binding of  1 PI to the CXCR4/HLE CS /CXCL12 complex during cell migration thereby facilitating adult thymopoiesis. In contrast to all other patients in the study who exhibited a 3-week cycle, patient Gamma exhibited a 2-week cycle suggesting some parts of the thymopoiesis cycle were intact, but that at least one step was impaired. This patient was documented to have lost the ability to respond to PPD which is a T lymphocyte-mediated response and is clinically interpreted to mean loss of immune function. In support of this hypothesis, there was no evidence of increased numbers of T lymphocytes in this patient suggesting that progenitor cells were being released from bone marrow, but not establishing residence in the stem cell niche of the thymus.
The phenomenon that PI ZZ patients exhibit deficient hepatocyte-synthesized  1 PI from birth, yet manifest normal numbers of CD4 + lymphocytes suggests there are additional considerations during fetal thymic selection, possibly the thymic or stromal supply of  1 PI. Both myeloid and lymphoid cells are known to synthesize  1 PI in bone marrow (16, 17) Alternatively, the role of  1 PI in hematopoiesis might be supplanted by other proteinase inhibitors during fetal development.
The duration of benefit for 2 wks, but not 5 wks, post-treatment suggests  1 PI augmentation might be effective with less frequent than weekly administration. Our results predict that  1 PI augmentation may overcome a localized pathologic system thereby allowing the immune system to recover and regain production of normal numbers of CD4 + lymphocytes in a subset of HIV-1 + patients who are on antiretroviral therapy and have functioning lymphatic and hematopoietic tissue. cells/ml for 3 days in the presence of antibodies reactive with CD2, CD3, and CD28 as described in Methods. Cells from patient Alpha were isolated after 11 weeks of Zemaira ® therapy. Cells from patient Delta were isolated at baseline. Culture supernatants were simultaneously measured for cytokine release (Table 2 
BRISTOW et al:  1 Antitrypsin therapy increases CD4
+ lymphocytes
